Skip to main content

Metabolic Imaging with RF Antennas to predict Chemotherapy Efficacy

Objective

Metabolic Imaging with RF Antennas to predict Chemotherapy Efficacy: We will validate the phospholipid biomarker that can predict response of chemotherapy in patients with breast cancer using the most powerful MRI system in the world. In particular the ratio of phosphoethanolamine (PE) to glycerophosphocholine (GPC), metabolites from the build up and breakdown of cell membranes, have been shown to increase accuracy in prediction of chemotherapy response from 75% to 96% [1]. At the clinically available field strength of 7T, we have recently demonstrated that we can image these phospholipid biomarkers non-invasively. In order to assess accuracy and bring the detection of the biomarker to FDA approval, we will spin out a validation study to investigate the accuracy in detecting the biomarker by comparing the results from the same subjects obtained at clinical MRI as well as at 10.5T MRI. The innovation idea is linked to the Non-Invasive-Chemistry-Imaging (NICI) project of FET-OPEN-01-2016-2017-801075. More specifically to the deliverable D6.1: “List of groups and stakeholders for targeted dissemination”. Here the potential of the NICI project that uses multi-nuclear 7T MRI in patients with metastasis in liver was shown to the stakeholders in breast cancer imaging (joint meeting of International Society of Magnetic Resonance in Medicine (ISMRM) with EUropean Society Of Breast Imaging (Eusobi) in Las Vegas 2018). The importance of imaging chemistry was immediately recognised by all medical doctors present (radiology, surgery and oncology), and fast track to FDA clearance was discussed. By establishing a small consortium of the UMC Utrecht that leads the project, a newly formed spin out company that provides the 7T and 10.5T specific hardware, and University of Minnesota that has access to patients and houses the world’s strongest MRI, we will conduct the biomarker validation in 10 subjects scanned at both systems.

Field of science

  • /medical and health sciences/clinical medicine/surgery
  • /medical and health sciences/clinical medicine/radiology
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer

Call for proposal

H2020-FETOPEN-2018-2019-2020-03
See other projects for this call

Funding Scheme

CSA - Coordination and support action

Coordinator

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Address
Heidelberglaan 100
3584 CX Utrecht
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 18 750

Participants (2)

REGENTS OF UNIVERSITY OF MINNESOTA
United States
EU contribution
€ 18 750
Address
Oak Street Se 200 Mcnamara Alumni Center 450
55455 2070 Minneapolis Mn
Activity type
Higher or Secondary Education Establishments
WAVETRONICA BV
Netherlands
EU contribution
€ 62 500
Address
Padualaan 8 Room Z109
3584 CH Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)